118 related articles for article (PubMed ID: 31535668)
41. Malignancy risk and characteristics of thyroid nodules with two consecutive results of atypia of undetermined significance or follicular lesion of undetermined significance on cytology.
Park VY; Kim EK; Kwak JY; Yoon JH; Moon HJ
Eur Radiol; 2015 Sep; 25(9):2601-7. PubMed ID: 25740802
[TBL] [Abstract][Full Text] [Related]
42. Genetic markers differentiating follicular thyroid carcinoma from benign lesions.
Freitas BC; Cerutti JM
Mol Cell Endocrinol; 2010 May; 321(1):77-85. PubMed ID: 19932149
[TBL] [Abstract][Full Text] [Related]
43. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.
Eszlinger M; Paschke R
Mol Cell Endocrinol; 2010 Jun; 322(1-2):29-37. PubMed ID: 20083161
[TBL] [Abstract][Full Text] [Related]
44. Low malignancy risk of thyroid follicular lesion of undetermined significance in patients from post-endemic areas.
Słowińska-Klencka D; Woźniak E; Wojtaszek M; Popowicz B; Sporny S; Klencki M
Eur J Endocrinol; 2013 Apr; 168(4):621-30. PubMed ID: 23341072
[TBL] [Abstract][Full Text] [Related]
45. Next-Generation Sequencing Identifies a Highly Accurate miRNA Panel That Distinguishes Well-Differentiated Thyroid Cancer from Benign Thyroid Nodules.
Mazeh H; Deutch T; Karas A; Bogardus KA; Mizrahi I; Gur-Wahnon D; Ben-Dov IZ
Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):858-863. PubMed ID: 30049841
[No Abstract] [Full Text] [Related]
46. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
[TBL] [Abstract][Full Text] [Related]
47. Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia.
Madsen MB; Kiss K; Cilius Nielsen F; Bennedbæk FN; Rossing M
Front Endocrinol (Lausanne); 2020; 11():146. PubMed ID: 32265839
[TBL] [Abstract][Full Text] [Related]
48. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
49. Follicular lesion of undetermined significance in thyroid FNA revisited.
Walts AE; Mirocha J; Bose S
Diagn Cytopathol; 2014 Jan; 42(1):18-22. PubMed ID: 23894017
[TBL] [Abstract][Full Text] [Related]
50. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
Borrelli N; Ugolini C; Giannini R; Antonelli A; Giordano M; Sensi E; Torregrossa L; Fallahi P; Miccoli P; Basolo F
Cancer Cytopathol; 2016 May; 124(5):340-9. PubMed ID: 26749005
[TBL] [Abstract][Full Text] [Related]
51. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
Chung KW; Yang SK; Lee GK; Kim EY; Kwon S; Lee SH; Park DJ; Lee HS; Cho BY; Lee ES; Kim SW
Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
[TBL] [Abstract][Full Text] [Related]
52. The role of core needle biopsy in the preoperative diagnosis of follicular neoplasm of the thyroid.
Min HS; Kim JH; Ryoo I; Jung SL; Jung CK
APMIS; 2014 Oct; 122(10):993-1000. PubMed ID: 24673498
[TBL] [Abstract][Full Text] [Related]
53. Benign call rate and molecular test result distribution of ThyroSeq v3.
Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
[TBL] [Abstract][Full Text] [Related]
54. Atypia of undetermined significance and follicular lesions of undetermined significance: sonographic assessment for prediction of the final diagnosis.
Kamaya A; Lewis GH; Liu Y; Akatsu H; Kong C; Desser TS
J Ultrasound Med; 2015 May; 34(5):767-74. PubMed ID: 25911708
[TBL] [Abstract][Full Text] [Related]
55. Bethesda Category III, IV, and V Thyroid Nodules: Can Nodule Size Help Predict Malignancy?
Kiernan CM; Solórzano CC
J Am Coll Surg; 2017 Jul; 225(1):77-82. PubMed ID: 28223197
[TBL] [Abstract][Full Text] [Related]
56. Incidence and malignancy rates of indeterminate pediatric thyroid nodules.
Wang H; Mehrad M; Ely KA; Liang J; Solórzano CC; Neblett WW; Coogan AC; Weiss VL
Cancer Cytopathol; 2019 Apr; 127(4):231-239. PubMed ID: 30768868
[TBL] [Abstract][Full Text] [Related]
57. The Impact of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma on Rates of Malignancy for Fine-Needle Aspiration Diagnostic Categories.
Strickland KC; Howitt BE; Marqusee E; Alexander EK; Cibas ES; Krane JF; Barletta JA
Thyroid; 2015 Sep; 25(9):987-92. PubMed ID: 26114752
[TBL] [Abstract][Full Text] [Related]
58. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
[TBL] [Abstract][Full Text] [Related]
59. Expression of micro-ribonucleic acids in thyroid nodules and serum to discriminate between follicular adenoma and cancer in patients with a fine needle aspiration biopsy classified as suspicious for follicular neoplasm: A preliminary study.
Świrta JS; Wątor G; Seweryn M; Kapusta P; Barczyński M; Wołkow P
Adv Clin Exp Med; 2023 Sep; 32(9):997-1007. PubMed ID: 36897102
[TBL] [Abstract][Full Text] [Related]
60. The utility of combined mutation analysis and microRNA classification in reclassifying cancer risk of cytologically indeterminate thyroid nodules.
Banizs AB; Silverman JF
Diagn Cytopathol; 2019 Apr; 47(4):268-274. PubMed ID: 30565896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
